Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.Any investor who owned Viking Therapeutics (VKTX -0.23%) before November of last year is sure to be disappointed and maybe even a little worried. Shares are down nearly 60% since October last year and lower to the tune of 68% from their early 2024 high after soaring in 2023. Yikes.If you were on this wild ride, don't panic yet. And for interested newcomers, the sell-off may arguably be a buying opportu ...